Affordable Access

deepdyve-link
Publisher Website

Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes.

Authors
  • Oldfield, Lucy1
  • Evans, Anthony1
  • Rao, Rohith Gopala1
  • Jenkinson, Claire1
  • Purewal, Tejpal2
  • Psarelli, Eftychia E1
  • Menon, Usha3
  • Timms, John F4
  • Pereira, Stephen P5
  • Ghaneh, Paula1
  • Greenhalf, William1
  • Halloran, Christopher1
  • Costello, Eithne6
  • 1 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, UK.
  • 2 Department of Diabetes and Endocrinology, Royal Liverpool University Hospital, UK.
  • 3 Institute of Clinical Trials and Methodology, University College London, UK.
  • 4 Women's Cancer, Institute for Women's Health, University College London, UK.
  • 5 Institute for Liver and Digestive Health, University College London, UK.
  • 6 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, UK. Electronic address: [email protected]
Type
Published Article
Journal
EBioMedicine
Publisher
Elsevier
Publication Date
Jan 01, 2022
Volume
75
Pages
103802–103802
Identifiers
DOI: 10.1016/j.ebiom.2021.103802
PMID: 34990893
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Screening for pancreatic ductal adenocarcinoma (PDAC) in populations at high risk is recommended. Individuals with new-onset type 2 diabetes mellitus (NOD) are the largest high-risk group for PDAC. To facilitate screening, we sought biomarkers capable of stratifying NOD subjects into those with type 2 diabetes mellitus (T2DM) and those with the less prevalent PDAC-related diabetes (PDAC-DM), a form of type 3c DM commonly misdiagnosed as T2DM. Using mass spectrometry- and immunoassay-based methodologies in a multi-stage analysis of independent sample sets (n=443 samples), blood levels of 264 proteins were considered using Ingenuity Pathway Analysis, literature review and targeted training and validation. Of 30 candidate biomarkers evaluated in up to four independent patient sets, 12 showed statistically significant differences in levels between PDAC-DM and T2DM. The combination of adiponectin and interleukin-1 receptor antagonist (IL-1Ra) showed strong diagnostic potential, (AUC of 0.91; 95% CI: 0.84-0.99) for the distinction of T3cDM from T2DM. Adiponectin and IL-1Ra warrant further consideration for use in screening for PDAC in individuals newly-diagnosed with T2DM. North West Cancer Research, UK, Cancer Research UK, Pancreatic Cancer Action, UK. Crown Copyright © 2021. Published by Elsevier B.V. All rights reserved.

Report this publication

Statistics

Seen <100 times